NEU 0.35% $19.97 neuren pharmaceuticals limited

NEU chart, page-311

  1. 351 Posts.
    lightbulb Created with Sketch. 38
    Thanks so much Crem.. if I could indulge you/another expert with one more follow up question. I believe the patent for Trof in the US/Europe expires in Jan 2032. I assume after that, Trof would be competed with and the price/royalties would reduce significantly? Accordingly the large cashflows are highly finite to the patent/exclusivity period hence the 10x multiple is applied. Is such analysis incorrect, or can you elaborate on why the 25x is more appropriate given the finite earnings window ahead? Or have I got this all wrong?!
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.